Carlos Rangel Rodrigues

List of Publications by Year
in descending order

140 papers	3,816 citations	126907 33 h-index	161849 54 g-index
143 all docs	143 docs citations	143 times ranked	5612 citing authors

#	Article	IF	Citations
1	Ethylhexyl methoxycinnamate and butyl methoxydibenzoylmethane: Toxicological effects on marine biota and human concerns. Journal of Applied Toxicology, 2022, 42, 73-86.	2.8	12
2	Antimycobacterial and anti-inflammatory activities of thiourea derivatives focusing on treatment approaches for severe pulmonary tuberculosis. Bioorganic and Medicinal Chemistry, 2022, 53, 116506.	3.0	15
3	Molecular modelling and dynamics simulations of single-wall carbon nanotube as a drug carrier: New insights into the drug-loading process. Journal of Molecular Graphics and Modelling, 2022, 113, 108145.	2.4	7
4	Eugenia sulcata (Myrtaceae) Nanoemulsion Enhances the Inhibitory Activity of the Essential Oil on P2X7R and Inflammatory Response In Vivo. Pharmaceutics, 2022, 14, 911.	4.5	9
5	Development of novel montmorillonite-based sustained release system for oral bromopride delivery.. European Journal of Pharmaceutical Sciences, 2022, 175, 106222.	4.0	11
6	Alternative Methods for Pulmonary-Administered Drugs Metabolism: a Breath of Change. Mini-Reviews in Medicinal Chemistry, 2022, 22, .	2.4	0
7	Clofazimine functionalized polymeric nanoparticles for brain delivery in the tuberculosis treatment. International Journal of Pharmaceutics, 2021, 602, 120655.	5.2	19
8	Benign prostatic hyperplasia therapy through liquisolid technology composed of polymer-layered nanocomposites based on silicate that contain babassu oil and copaiba oil-resin. Journal of Drug Delivery Science and Technology, 2021, 64, 102586.	3.0	3
9	Development of rivaroxaban microemulsion-based hydrogel for transdermal treatment and prevention of venous thromboembolism. Colloids and Surfaces B: Biointerfaces, 2021, 206, 111978.	5.0	6
10	Diterpenes isolated from Canistrocarpus cervicornis with virucidal activity against HIV-1: an in silico evaluation. Natural Product Research, 2021, , 1-5.	1.8	1
11	Forced degradation studies of norepinephrine and epinephrine from dental anesthetics: Development of stabilityâ€indicating HPLC method and in silico toxicity evaluation. Biomedical Chromatography, 2020, 34, e4832.	1.7	7
12	Design, synthesis, inÂvitro and in silico studies of novel 4-oxoquinoline ribonucleoside derivatives as HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2020, 194, 112255.	5.5	12
13	Full-factorial design for statistical planning of attritor milling parameters and evaluation of effects on particle size and structure of sodium-montmorillonite. Engineering Research Express, 2020, 2, 015050.	1.6	0
14	Molecular dynamic simulations of full-length human purinergic receptor subtype P2X7 bonded to potent inhibitors. European Journal of Pharmaceutical Sciences, 2020, 152, 105454.	4.0	11
15	In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. Anais Da Academia Brasileira De Ciencias, 2020, 92, e20191445.	0.8	3
16	Nanoparticles Loaded with a New Thiourea Derivative: Development and In vitro Evaluation Against Leishmania amazonensis. Current Drug Delivery, 2020, 17, 694-702.	1.6	4
17	Synthesis, In Vitro and In Silico Studies of Indolequinone Derivatives against Clinically Relevant Bacterial Pathogens. Current Topics in Medicinal Chemistry, 2020, 20, 192-208.	2.1	5
18	Antiviral Drug Discovery and Development for Mayaro Fever â€“ What do we have so far?. Mini-Reviews in Medicinal Chemistry, 2020, 20, 921-928.	2.4	7

#	Article	IF	Citations
19	Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response. Journal of Bioenergetics and Biomembranes, 2019, 51, 277-290.	2.3	15
20	Synthesis, Biological Evaluation, and Molecular Modeling Studies of New Thiadiazole Derivatives as Potent P2X7 Receptor Inhibitors. Frontiers in Chemistry, 2019, 7, 261.	3.6	15
21	Photoprotection assessment of olive (Olea europaea L.) leaves extract standardized to oleuropein: In vitro and in silico approach for improved sunscreens. Journal of Photochemistry and Photobiology B: Biology, 2019, 193, 162-171.	3.8	43
22	Molecular modeling as a design tool for sunscreen candidates: a case study of bemotrizinol. Journal of Molecular Modeling, 2019, 25, 362.	1.8	6
23	A promising oral fucoidan-based antithrombotic nanosystem: development, activity and safety. Nanotechnology, 2018, 29, 165102.	2.6	25
24	Molecular modeling for the investigation of UV absorbers for sunscreens: Triazine and benzotriazole derivatives. Journal of Photochemistry and Photobiology A: Chemistry, 2018, 356, 219-229.	3.9	22
25	A comprehensive review of chalcone derivatives as antileishmanial agents. European Journal of Medicinal Chemistry, 2018, 150, 920-929.	5.5	100
26	Molecular modeling and dynamic simulations of agglutinin-like family members from Candida albicans: New insights into potential targets for the treatment of candidiasis. Journal of Biomolecular Structure and Dynamics, 2018, 36, 4352-4365.	3.5	4
27	Development and Characterization of Dapsone Cocrystal Prepared by Scalable Production Methods. AAPS PharmSciTech, 2018, 19, 2687-2699.	3.3	27
28	A synergistic nanoformulation of babassu and copaiba oils as natural alternative for prevention of benign prostatic hyperplasia. Journal of Drug Delivery Science and Technology, 2018, 47, 167-175.	3.0	7
29	Exploring 1,2,3-triazole derivatives by using in vitro and in silico assays to target new antifungal agents and treat Candidiasis. Medicinal Chemistry Research, 2017, 26, 680-689.	2.4	13
30	Oligopeptidase B and B2: comparative modelling and virtual screening as searching tools for new antileishmanial compounds. Parasitology, 2017, 144, 536-545.	1.5	11
31	Identification, characterization and in silico ADMET prediction of Roflumilast degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 126-133.	2.8	16
32	Synthesis and mechanistic evaluation of novel N â€™-benzylidene-carbohydrazide-1 H -pyrazolo[3,4 -b]pyridine derivatives as non-anionic antiplatelet agents. European Journal of Medicinal Chemistry, 2017, 135, 213-229.	5.5	25
33	Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 314-318.	2.2	6
34	1-Aryl-1 H - and 2-aryl-2 H -1,2,3-triazole derivatives blockade P2X7 receptor inÂvitro and inflammatory response inÂvivo. European Journal of Medicinal Chemistry, 2017, 139, 698-717.	5.5	36
35	Development and characterization of clay-polymer nanocomposite membranes containing sodium alendronate with osteogenic activity. Applied Clay Science, 2017, 146, 475-486.	5.2	16
36	Targeting <scp>CYP</scp>51 for drug design by the contributions of molecular modeling. Fundamental and Clinical Pharmacology, 2017, 31, 37-53.	1.9	19

#	Article	IF	Citations
37	Antileishmanial Thioureas: Synthesis, Biological Activity and <i>in Silico</i> Evaluations of New Promising Derivatives. Chemical and Pharmaceutical Bulletin, 2017, 65, 911-919.	1.3	17
38	Asymmetric bioreduction of Î²-ketoesters derivatives by Kluyveromyces marxianus: influence of molecular structure on the conversion and enantiomeric excess. Anais Da Academia Brasileira De Ciencias, 2017, 89, 1403-1415.	0.8	9
39	Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1591-1601.	5.2	15
40	New approaches in tailâ€bleeding assay in mice: improving an important method for designing new antiâ€thrombotic agents. International Journal of Experimental Pathology, 2016, 97, 285-292.	1.3	31
41	Design, Synthesis and Evaluation of New Fluoroamodiaquine Analogues. Chemical and Pharmaceutical Bulletin, 2016, 64, 594-601.	1.3	6
42	Development and Characterization of Nisin Nanoparticles as Potential Alternative for the Recurrent Vaginal Candidiasis Treatment. AAPS PharmSciTech, 2016, 17, 1421-1427.	3.3	37
43	Aqueous Molecular Dynamics Simulations of the M. tuberculosis Enoyl-ACP Reductase-NADH System and Its Complex with a Substrate Mimic or Diphenyl Ethers Inhibitors. International Journal of Molecular Sciences, 2015, 16, 23695-23722.	4.1	15
44	Probing insulin bioactivity in oral nanoparticles produced by ultrasonication-assisted emulsification/internal gelation. International Journal of Nanomedicine, 2015, 10, 5865.	6.7	31
45	Synthesis and Antiplatelet Activity of Antithrombotic Thiourea Compounds: Biological and Structure-Activity Relationship Studies. Molecules, 2015, 20, 7174-7200.	3.8	18
46	Sodium Montmorillonite/Amine-Containing Drugs Complexes: New Insights on Intercalated Drugs Arrangement into Layered Carrier Material. PLoS ONE, 2015, 10, e0121110.	2.5	27
47	Computational Studies of Benzoxazinone Derivatives as Antiviral Agents against Herpes Virus Type 1 Protease. Molecules, 2015, 20, 10689-10704.	3.8	7
48	Molecular modeling study of a series of amodiaquine analogues with antimalarial activity. Medicinal Chemistry Research, 2015, 24, 3529-3536.	2.4	5
49	Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimerâ€™s Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme. International Journal of Molecular Sciences, 2015, 16, 5235-5253.	4.1	12
50	Antimycobacterial and Anti-Inflammatory Activities of Substituted Chalcones Focusing on an Anti-Tuberculosis Dual Treatment Approach. Molecules, 2015, 20, 8072-8093.	3.8	44
51	Preparation and Evaluation of Chitosan Submicroparticles Containing Pilocarpine for Glaucoma Therapy. Current Drug Delivery, 2015, 12, 491-503.	1.6	9
52	Preparation and scale up of extended-release tablets of bromopride. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 291-300.	1.2	3
53	Structural model of haptoglobin and its complex with the anticoagulant ecotin variants: structureâ€“activity relationship study and analysis of interactions. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 256-262.	5.2	0
54	Titanium Dioxideâ€“Montmorillonite Nanocomposite as Photoprotective Agent Against Ultraviolet B Radiation-Induced Mutagenesis in Saccharomyces cerevisiae: A Potential Candidate for Safer Sunscreens. Journal of Pharmaceutical Sciences, 2014, 103, 2539-2545.	3.3	10

#	Article	IF	Citations
55	Novel isomannide-based peptide mimetics containing a tartaric acid backbone as serine protease inhibitors. Medicinal Chemistry Research, 2014, 23, 5305-5320.	2.4	6
56	Human thromboxane synthase: comparative modeling and docking evaluation with the competitive inhibitors Dazoxiben and Ozagrel. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 527-531.	5.2	15
57	Preparation and characterization of polymer/layered silicate pharmaceutical nanobiomaterials using high clay load exfoliation processes. Journal of Industrial and Engineering Chemistry, 2014, 20, 4094-4101.	5.8	13
58	Intestinal absorption of insulin nanoparticles: Contribution of M cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1139-1151.	3.3	73
59	Exploring N-Acylhydrazone Derivatives Against Clinical Resistant Bacterial Strains. Current Microbiology, 2014, 69, 357-364.	2.2	10
60	In vitro and in vivo analysis of the antithrombotic and toxicological profile of new antiplatelets N-acylhydrazone derivatives and development of nanosystems. Thrombosis Research, 2014, 134, 376-383.	1.7	31
61	Crystalline forms of nonprotein drugs filed in Brazil from 1995â€“2005. Pharmaceutical Patent Analyst, 2014, 3, 151-161.	1.1	0
62	Assessment of analytical techniques for characterization of crystalline clopidogrel forms in patent applications. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 229-242.	1.2	1
63	Therapeutic Nanosystems for Oral Administration of Insulin. Current Pharmaceutical Biotechnology, 2014, 15, 620-628.	1.6	9
64	Intestinal Uptake of Insulin Nanoparticles: Facts or Myths?. Current Pharmaceutical Biotechnology, 2014, 15, 629-638.	1.6	21
65	In Vitroâ€“In Vivo Correlation of Efavirenz Tablets Using GastroPlusÂ®. AAPS PharmSciTech, 2013, 14, 1244-1254.	3.3	53
66	Molecular Modeling of a Phenylâ€Amidine Class of NMDA Receptor Antagonists and the Rational Design of New Triazolylâ€Amidine Derivatives. Chemical Biology and Drug Design, 2013, 81, 185-197.	3.2	6
67	Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia. Journal of Pharmaceutical Sciences, 2013, 102, 4057-4064.	3.3	14
68	Nanostructured systems containing babassu (Orbignya speciosa) oil as a potential alternative therapy for benign prostatic hyperplasia. International Journal of Nanomedicine, 2013, 8, 3129.	6.7	22
69	Molecular Docking Studies of Marine Diterpenes as Inhibitors of Wild-Type and Mutants HIV-1 Reverse Transcriptase. Marine Drugs, 2013, 11, 4127-4143.	4.6	17
70	Hologram quantitative structure–activity relationship and comparative molecular field analysis studies within a series of tricyclic phthalimide HIV-1 integrase inhibitors. Drug Design, Development and Therapy, 2013, 7, 953.	4.3	5
71	Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. International Journal of Nanomedicine, 2012, 7, 5175.	6.7	22
72	4-(1H-Pyrazol-1-yl) Benzenesulfonamide Derivatives: Identifying New Active Antileishmanial Structures for Use against a Neglected Disease. Molecules, 2012, 17, 12961-12973.	3.8	23

#	Article	IF	Citations
73	Molecular Modeling Studies of the Structural, Electronic, and UV Absorption Properties of Benzophenone Derivatives. Journal of Physical Chemistry A, 2012, 116, 10927-10933.	2.5	33
74	Hologram QSAR Models of 4-[(Diethylamino)methyl]-phenol Inhibitors of Acetyl/Butyrylcholinesterase Enzymes as Potential Anti-Alzheimer Agents. Molecules, 2012, 17, 9529-9539.	3.8	21
75	Sulphonamide and sulphonyl-hydrazone cyclic imide derivatives: Antinociceptive activity, molecular modeling and In Silico ADMET screening. Archives of Pharmacal Research, 2012, 35, 1713-1722.	6.3	18
76	Tuberculosis: Finding a New Potential Antimycobacterium Derivative in a Aldehydeâ€"Arylhydrazoneâ€"Oxoquinoline Series. Current Microbiology, 2012, 65, 455-460.	2.2	9
77	HIV-1 Reverse Transcriptase: a potential target for marine products. Revista Brasileira De Farmacognosia, 2012, 22, 881-888.	1.4	7
78	Application of 4D-QSAR Studies to a Series of Raloxifene Analogs and Design of Potential Selective Estrogen Receptor Modulators. Molecules, 2012, 17, 7415-7439.	3.8	9
79	Residue-Ligand Interaction Energy (ReLIE) on a Receptor-Dependent 3D-QSAR Analysis of S- and NH-DABOs as Non-Nucleoside Reverse Transcriptase Inhibitors. Molecules, 2012, 17, 7666-7694.	3.8	6
80	Receptorâ€Dependent 4Dâ€QSAR Analysis of Peptidemimetic Inhibitors of Trypanosoma cruzi Trypanothione Reductase with Receptorâ€Based Alignment. Chemical Biology and Drug Design, 2012, 79, 740-748.	3.2	15
81	Preparation and Evaluation of a New Nano Pharmaceutical Excipients and drug Delivery System Based in Polyvinylpyrrolidone and Silicates. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 17.	2.1	9
82	Preparation and evaluation of antimicrobial activity of nanosystems for the control of oral pathogens Streptococcus mutans and Candida albicans. International Journal of Nanomedicine, 2011, 6, 2581.	6.7	20
83	Preparation and evaluation of lidocaine hydrochloride in cyclodextrin inclusion complexes for development of stable gel in association with chlorhexidine gluconate for urogenital use. International Journal of Nanomedicine, 2011, 6, 1143.	6.7	13
84	Synthesis and antileishmanial activity of new 1-aryl-1H-pyrazole-4-carboximidamides derivatives. Journal of the Brazilian Chemical Society, 2011, 22, 352-358.	0.6	20
85	Trypanosoma cruzi: Insights into naphthoquinone effects on growth and proteinase activity. Experimental Parasitology, 2011, 127, 160-166.	1.2	29
86	Synthesis, antitubercular activity, and SAR study of N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides. Bioorganic and Medicinal Chemistry, 2011, 19, 5605-5611.	3.0	53
87	Identification of Nor-Î²-Lapachone Derivatives as Potential Antibacterial Compounds against Enterococcus faecalis Clinical Strain. Current Microbiology, 2011, 62, 684-689.	2.2	21
88	Oxoquinoline Derivatives: Identification and Structureâ€"Activity Relationship (SAR) Analysis of New Anti-HSV-1 Agents. Current Microbiology, 2011, 62, 1349-1354.	2.2	9
89	Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE). European Journal of Medicinal Chemistry, 2011, 46, 39-51.	5.5	30
90	Synthesis and anticancer activities of some novel 2-(benzo[d]thiazol-2-yl)-8-substituted-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones. European Journal of Medicinal Chemistry, 2011, 46, 1448-1452.	5.5	33

#	Article	IF	Citations
91	Looking at the proteases from a simple perspective. Journal of Molecular Recognition, 2011, 24, 165-181.	2.1	32
92	Trimethoxy-chalcone derivatives inhibit growth of Leishmania braziliensis: Synthesis, biological evaluation, molecular modeling and structureâ€“activity relationship (SAR). Bioorganic and Medicinal Chemistry, 2011, 19, 5046-5052.	3.0	47
93	Comparative Analysis ofViperidaeVenoms Antibacterial Profile: a Short Communication for Proteomics. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-4.	1.2	23
94	Brown Seaweed Defensive Chemicals: A Structure-activity Relationship Approach for the Marine Environment. Natural Product Communications, 2009, 4, 1934578X0900400.	0.5	6
95	Antiophidian sera sterility control: topics in perspective. Brazilian Journal of Pharmaceutical Sciences, 2009, 45, 401-415.	1.2	1
96	Leishmania amazonensis Growth Inhibitors: Biological and Theoretical Features of Sulfonamide 4-Methoxychalcone Derivatives. Current Microbiology, 2009, 59, 374-379.	2.2	17
97	Molecular docking of a series of peptidomimetics in the trypanothione binding site of T. cruzi Trypanothione Reductase. Journal of Molecular Graphics and Modelling, 2009, 28, 330-335.	2.4	9
98	Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates. European Journal of Medicinal Chemistry, 2009, 44, 373-383.	5.5	201
99	Synthesis, biological evaluation and SAR of sulfonamide 4-methoxychalcone derivatives with potential antileishmanial activity. European Journal of Medicinal Chemistry, 2009, 44, 755-763.	5.5	49
100	Synthesis, antichagasic in vitro evaluation, cytotoxicity assays, molecular modeling and SAR/QSAR studies of a 2-phenyl-3-(1-phenyl-1H-pyrazol-4-yl)-acrylic acid benzylidene-carbohydrazide series. Bioorganic and Medicinal Chemistry, 2009, 17, 295-302.	3.0	69
101	Synthesis, antiplatelet and in silico evaluations of novel N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides. Bioorganic and Medicinal Chemistry, 2009, 17, 3713-3719.	3.0	77
102	Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives. Bioorganic and Medicinal Chemistry, 2009, 17, 5476-5481.	3.0	36
103	Synthesis, biological, and theoretical evaluations of new 1,2,3-triazoles against the hemolytic profile of the Lachesis muta snake venom. Bioorganic and Medicinal Chemistry, 2009, 17, 7429-7434.	3.0	36
104	Integrin inhibitors from snake venom: Exploring the relationship between the structure and activity of RGD-peptides. Archives of Biochemistry and Biophysics, 2009, 482, 25-32.	3.0	28
105	Structural and Pharmacological Features of Phospholipases A2 from Snake Venoms. Protein and Peptide Letters, 2009, 16, 899-907.	0.9	43
106	Identification of a Potential Lead Structure for Designing New Antimicrobials to Treat Infections Caused by Staphylococcus epidermidis-Resistant Strains. Current Microbiology, 2008, 57, 463-468.	2.2	11
107	Leishmaniasis treatmentâ€”a challenge that remains: a review. Parasitology Research, 2008, 103, 1-10.	1.6	232
108	Just working with the cellular machine. Biochemistry and Molecular Biology Education, 2008, 36, 120-124.	1.2	6

#	Article	IF	Citations
109	SAR of a series of anti-HSV-1 acridone derivatives, and a rational acridone-based design of a new anti-HSV-1 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridine series. Bioorganic and Medicinal Chemistry, 2008, 16, 313-321.	3.0	46
110	Antibacterial profile against drug-resistant Staphylococcus epidermidis clinical strain and structureâ€“activity relationship studies of 1H-pyrazolo[3,4-b]pyridine and thieno[2,3-b]pyridine derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 8196-8204.	3.0	57
111	3D-QSAR CoMFA of a Series of DABO Derivatives as HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors. Journal of Chemical Information and Modeling, 2008, 48, 1706-1715.	5.4	16
112	Identification and characterization of a new member of snake venom thrombin inhibitors from Bothrops insularis using a proteomic approach. Toxicon, 2008, 51, 659-671.	1.6	16
113	Preparation and Evaluation of Inclusion Complexes of Commercial Sunscreens in Cyclodextrins and Montmorillonites: Performance and Substantivity Studies. Drug Development and Industrial Pharmacy, 2008, 34, 536-546.	2.0	14
114	The Preparation and Evaluation of Sodium and Alkylammonium Montmorillonite and Polysaccharide Nanocomposites as Sustained Release Excipients. Polymer-Plastics Technology and Engineering, 2008, 47, 1256-1264.	1.9	8
115	Speciation of antimony (III) and antimony (V) using hydride generation for meglumine antimoniate pharmaceutical formulationsquality control. Memorias Do Instituto Oswaldo Cruz, 2008, 103, 130-137.	1.6	16
116	Synthesis of new 4-(phenylamino)thieno[2,3-b]pyridines and derivatives of the novel benzo[b]thieno[3,2-h][1,6]naphthyridine tetracyclic system. Arkivoc, 2008, 2008, 77-87.	0.5	17
117	Synthesis, in vitro evaluation, and SAR studies of a potential antichagasic 1H-pyrazolo[3,4-b]pyridine series. Bioorganic and Medicinal Chemistry, 2007, 15, 211-219.	3.0	69
118	Structureâ€“function inferences based on molecular modeling, sequence-based methods and biological data analysis of snake venom lectins. Toxicon, 2006, 48, 690-701.	1.6	23
119	Trypanocidal agents with low cytotoxicity to mammalian cell line: A comparison of the theoretical and biological features of lapachone derivatives. Bioorganic and Medicinal Chemistry, 2006, 14, 5459-5466.	3.0	78
120	Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives. Bioorganic and Medicinal Chemistry, 2006, 14, 8644-8653.	3.0	193
121	Design, synthesis, SAR, and biological evaluation of new 4-(phenylamino)thieno[2,3-b]pyridine derivatives. Bioorganic and Medicinal Chemistry, 2006, 14, 5765-5770.	3.0	92
122	CURRENT STATUS OF SNAKE VENOM THROMBIN-LIKE ENZYMES. Toxin Reviews, 2006, 25, 291-318.	3.4	18
123	Development and validation of a HPLC-UV method for the determination in didanosine tablets. Journal of Pharmaceutical and Biomedical Analysis, 2005, 38, 751-756.	2.8	12
124	Snake Venom: Any Clue for Antibiotics and CAM?. Evidence-based Complementary and Alternative Medicine, 2005, 2, 39-47.	1.2	42
125	Snake venom thrombin-like enzymes: from reptilase to now. Cellular and Molecular Life Sciences, 2004, 61, 843-856.	5.4	159
126	Solving an ethical issue involved in experimentation with animals in a brazilian teaching laboratory. Biochemistry and Molecular Biology Education, 2004, 32, 395-399.	1.2	1

#	Article	IF	Citations
127	Chiral separation of Î³-butyrolactone derivatives by gas chromatography on 2,3-di-O-methyl-6-O-tert.-butyldimethylsilyl-Î²-cyclodextrin. Journal of Chromatography A, 2003, 985, 321-331.	3.7	11
128	Design, Synthesis, and Pharmacological Profile of Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine Isosteres:Â A New Class of Potent and Selective Acetylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 1144-1152.	6.4	101
129	Structureâ^'Activity Relationships of the Antimalarial Agent Artemisinin. 6. The Development of Predictive In Vitro Potency Models Using CoMFA and HQSAR Methodologies. Journal of Medicinal Chemistry, 2002, 45, 292-303.	6.4	78
130	A quÃmica medicinal de N-acilidrazonas: novos compostos-protÃ³tipos de fÃ¡rmacos analgÃ©sicos, antiinflamatÃ³rios e anti-trombÃ³ticos. Quimica Nova, 2002, 25, 129-148.	0.3	42
131	Molecular modeling of novel 1H-pyrazolo[3,4-b]pyridine derivatives designed as isosters of the antimalarial mefloquine. Computational and Theoretical Chemistry, 2002, 579, 31-39.	1.5	28
132	CoMFA and HQSAR of acylhydrazide cruzain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1537-1541.	2.2	36
133	Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1533-1535.	2.2	24
134	Highly diastereoselective mercury-mediated synthesis of functionalized 2-azabicyclo[3.3.0]octane derivatives. Tetrahedron Letters, 2002, 43, 1607-1611.	1.4	12
135	Design and Synthesis of Novel Potent Antinociceptive Agents: Methyl-imidazolyl N-Acylhydrazone Derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 2243-2248.	3.0	47
136	Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists. European Journal of Pharmaceutical Sciences, 2000, 11, 285-290.	4.0	37
137	A possible molecular mechanism for the inhibition of cysteine proteases by salicylaldehyde N-acylhydrazones and related compounds. Computational and Theoretical Chemistry, 2000, 505, 11-17.	1.5	36
138	Chiral Gas Chromatographic Separation of 2-Oxabicyclo[3.3.0]octane Derivatives and Their Synthetic Precursors. Analytical Chemistry, 2000, 72, 3056-3062.	6.5	5
139	Modelagem Molecular: Uma Ferramenta para o Planejamento Racional de FÃ¡rmacos em QuÃmica Medicinal. Quimica Nova, 1997, 20, 300-310.	0.3	18
140	A semiempirical study of pyrazole acylhydrazones as potential antimalarial agents. International Journal of Quantum Chemistry, 1996, 60, 1835-1843.	2.0	8